Viventia Biotechnologies Inc.

Viventia Biotechnologies Inc.

Viventia Biotechnologies Inc., a biopharmaceutical company, offers a portfolio of novel antibody-based drugs for the treatment of cancer. Its lead product, Proxinium is used for the treatment of head and neck cancer. The company also offers Vicinium, a product for the treatment of bladder cancer; and VB6-845, a product for the treatment of solid tumors. Viventia specializes in the discovery and development of a portfolio of monoclonal antibodies for the treatment of common cancers. It also has a location in Winnipeg, Canada. The company was formerly known as Novopharm Biotech, Inc. and changed its name to Viventia Biotech, Inc. in 2000. The company was is headquartered in Mississauga, Canada. As of December 28, 2005, Viventia Biotechnologies Inc. operates as a subsidiary of Dan Family Holdings, Ltd.

Contact Details

Office Address

Viventia Biotechnologies Inc.
7895 Tranmere Drive, Suite 204
Mississauga, Ontario, Canada L5S1V9
Phone: (905) 362-2973
Fax: (905) 362-2981


Chief Executive Officer

Dr. Nick Glover

Chief Financial Officer and Corporate Secretary

Mr. Michael A. Byrne

Business Reviews for Viventia Biotechnologies Inc.

Related Companies